Global X Management Company’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-223,954
Closed -$5.39M 1073
2017
Q3
$5.39M Buy
223,954
+11,292
+5% +$255K 0.15% 183
2017
Q2
$4.56M Buy
212,662
+6,068
+3% +$122K 0.14% 191
2017
Q1
$3.54M Buy
206,594
+566
+0.3% +$9.86K 0.13% 195
2016
Q4
$3.69M Sell
206,028
-82,390
-29% -$1.49M 0.16% 166
2016
Q3
$6M Sell
288,418
-20,454
-7% -$507K 0.27% 144
2016
Q2
$8.31M Buy
308,872
+7,748
+3% +$212K 0.42% 78
2016
Q1
$8.16M Sell
301,124
-10,180
-3% -$273K 0.52% 54
2015
Q4
$9.04M Sell
311,304
-8,940
-3% -$247K 0.61% 36
2015
Q3
$8.69M Sell
320,244
-12,918
-4% -$366K 0.65% 31
2015
Q2
$9.12M Buy
333,162
+8,160
+3% +$229K 0.5% 61
2015
Q1
$8.68M Sell
325,002
-18,174
-5% -$418K 0.49% 68
2014
Q4
$7.26M Sell
343,176
-28,188
-8% -$630K 0.4% 79
2014
Q3
$8.84M Sell
371,364
-5,818
-2% -$134K 0.48% 87
2014
Q2
$8.71M Buy
377,182
+10,870
+3% +$240K 0.5% 86
2014
Q1
$8.36M Buy
366,312
+14,712
+4% +$313K 0.57% 90
2013
Q4
$6.5M Sell
351,600
-5,500
-2% -$95.9K 0.55% 93
2013
Q3
$6.04M Buy
357,100
+13,730
+4% +$231K 0.72% 45
2013
Q2
$5.32M Buy
+343,370
New +$5.72M 0.87% 43

Other funds holding NVO

Global X Management Company's NVO Position: Q4 2017 in Review

Global X Management Company sold out of Novo Nordisk (NVO) in Q4 2017, closing a stake of 223,954 shares — an estimated $5.39M sold.

Global X Management Company first reported a position in NVO in Q2 2013 and held it in 18 quarters. The position peaked at $9.12M in Q2 2015. 552 funds tracked by Wall St. Rank hold NVO as of Q4 2017.

  • Global X Management Company reported no remaining Novo Nordisk position as of Q4 2017 after selling out during the quarter.
  • Global X Management Company sold 223,954 Novo Nordisk shares in Q4 2017, an estimated $5.39M.
  • Global X Management Company first reported a position in Novo Nordisk in Q2 2013 and held it in 18 quarters.
  • Global X Management Company's Novo Nordisk position peaked at $9.12M in Q2 2015.
  • 552 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2017.

Based on Global X Management Company's 13F filing for Q4 2017, filed 8 Feb 2018.